Insmed To Present at September Investor Conferences
Insmed (Nasdaq: INSM), a global biopharmaceutical company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Wells Fargo 2025 Healthcare Conference in Boston on September 5 at 8:00 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference in New York on September 9 at 4:50 p.m. ET.
Both presentations will be available via webcast through Insmed's investor relations website and will remain accessible for 30 days after the events.
Insmed (Nasdaq: INSM), azienda biofarmaceutica globale, ha annunciato la sua partecipazione a due conferenze per investitori previste a settembre 2025. La società interverrà al Wells Fargo 2025 Healthcare Conference a Boston il 5 settembre alle 8:00 ET e al Morgan Stanley 23rd Annual Global Healthcare Conference a New York il 9 settembre alle 16:50 ET.
Entrambe le presentazioni saranno trasmesse via webcast tramite il sito web delle relazioni con gli investitori di Insmed e resteranno disponibili per 30 giorni dopo gli eventi.
Insmed (Nasdaq: INSM), una compañía biofarmacéutica global, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2025. La compañía presentará en el Wells Fargo 2025 Healthcare Conference en Boston el 5 de septiembre a las 8:00 a.m. ET y en el Morgan Stanley 23rd Annual Global Healthcare Conference en Nueva York el 9 de septiembre a las 4:50 p.m. ET.
Ambas presentaciones estarán disponibles por webcast a través del sitio web de relaciones con inversores de Insmed y permanecerán accesibles durante 30 días después de los eventos.
Insmed (Nasdaq: INSM)은 글로벌 바이오제약 회사로서 2025년 9월에 개최되는 두 건의 투자자 컨퍼런스에 참여한다고 발표했습니다. 회사는 9월 5일 오전 8:00 ET에 보스턴에서 열리는 Wells Fargo 2025 Healthcare Conference와 9월 9일 오후 4:50 ET에 뉴욕에서 열리는 Morgan Stanley 23rd Annual Global Healthcare Conference에서 발표할 예정입니다.
두 발표 모두 Insmed의 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며 행사 종료 후 30일간 다시보기로 이용할 수 있습니다.
Insmed (Nasdaq: INSM), une entreprise biopharmaceutique mondiale, a annoncé sa participation à deux conférences pour investisseurs prévues en septembre 2025. La société présentera au Wells Fargo 2025 Healthcare Conference à Boston le 5 septembre à 8h00 ET et au Morgan Stanley 23rd Annual Global Healthcare Conference à New York le 9 septembre à 16h50 ET.
Les deux présentations seront diffusées en webcast via le site des relations investisseurs d'Insmed et resteront accessibles pendant 30 jours après les événements.
Insmed (Nasdaq: INSM), ein globales biopharmazeutisches Unternehmen, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 angekündigt. Das Unternehmen wird am Wells Fargo 2025 Healthcare Conference in Boston am 5. September um 8:00 Uhr ET und am Morgan Stanley 23rd Annual Global Healthcare Conference in New York am 9. September um 16:50 Uhr ET präsentieren.
Beide Präsentationen werden per Webcast über die Investor-Relations-Website von Insmed verfügbar sein und für 30 Tage nach den Veranstaltungen abrufbar bleiben.
- None.
- None.
- Wells Fargo 2025 Healthcare Conference in
Boston , on Friday, September 5, 2025, at 8:00 a.m. ET. - Morgan Stanely 23rd Annual Global Healthcare Conference in
New York , on Tuesday, September 9, 2025, at 4:50 p.m. ET.
These events will be webcast live and can be accessed by visiting the investor relations section of the Company's website at www.insmed.com. Webcasts will be archived for a period of 30 days following the conclusion of the live events.
About Insmed
Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including two approved therapies to treat chronic, debilitating lung diseases. The Company's early-stage programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.
Headquartered in
Contact:
Investors:
Bryan
Vice President, Investor Relations
(646) 812-4030
investor.relations@insmed.com
Media:
Claire Mulhearn
Vice President, Corporate Communications
(862) 842-6819
media@insmed.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-present-at-september-investor-conferences-302535055.html
SOURCE Insmed Incorporated